# Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients

> **NCT03749356** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 141 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** TacroBell SR cap.

## Key facts

- **NCT ID:** NCT03749356
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-12-04
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749356, "Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03749356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*